News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aastrom Biosciences, Inc. (ASTM) Completes Acquisition Of Sanofi (France) (SAN.PA)'s Cell Therapy And Regenerative Medicine Business



6/2/2014 9:18:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ANN ARBOR, Mich., June 2, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that the company has completed its acquisition of Sanofi's cell therapy and regenerative medicine (CTRM) business unit. As announced on April 21, 2014, Aastrom paid $4 million in cash and $2.5 million in a promissory note to acquire the CTRM business, which includes three marketed products in the United States and Europe as well as manufacturing and production centers in the U.S. and Denmark.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES